Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMarie-Christiane VekemansBGBjørn Tore GjertsenPVPeter J.M. Valk

Discussion

Loading...

Member takes

Overview

This analysis shows similar survival rates for autologous stem cell transplantation and chemotherapy in patients with AML, indicating treatment balance for adverse events.

Key Points

  • To compare outcomes of autologous stem cell transplantation versus consolidation chemotherapy in patients with acute myeloid leukemia after achieving remission.
  • Included newly diagnosed AML patients aged 18-65 years with favorable or intermediate risk based on ELN 2022 criteria
  • Compared outcomes between patients receiving autologous stem cell transplantation and those receiving consolidation chemotherapy after initial treatment
  • Analyzed relapse-free survival and overall survival using Cox proportional hazards regression model.
  • 5-year relapse-free survival was 60% for autologous stem cell transplantation and 56% for chemotherapy, p=0.70
  • 5-year overall survival was 72% for autologous stem cell transplantation and 71% for chemotherapy, p=0.76
  • Patients receiving autologous stem cell transplantation had shorter hospitalization duration compared to chemotherapy.

Cite This Study

Vekemans et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e537https://doi.org/10.1182/blood-2025-2517
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry2025 · 2 citations
  2. 2Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation2025
  3. 3CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  4. 4Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission2024 · 26 citations
  5. 5Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party2025